ADVA
24.3.2021 08:02:08 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that Vodafone Romania is using its carrier-grade network operating system (NOS) in a key trial of disaggregated cell site gateway (DCSG) technology in a live nationwide network. Built with ADVA’s Ensemble Activator software running on Edgecore’s new family of DCSG devices, the open multi-vendor transport network succeeded in carrying 2G, 3G, 4G and 5G traffic while also interoperating with Vodafone’s existing infrastructure. The trial is a key step towards Vodafone validating the disaggregated model.
“We are pleased to contribute to the innovation in the field of open telecom networks, facilitating the validation of the open cell site gateway concept in a live network scenario while following our existing standard practices and processes. It was a smooth introduction, proving that the concept of open telecom networks where hardware is decoupled from software is feasible – not only in core network platforms through virtualization and in mobile radio access networks through the OpenRAN, but now also in the IP transport layer,” said Catalin Buliga, CTO, Vodafone Romania. “Mobile networks have been for years locked into a limited number of traditional telecom equipment vendors. By investing in developing open networks, where the hardware and software are decoupled, we open the gate to a wide range of suppliers for hardware, a wide range of suppliers for software, we accelerate innovation and increase our resilience.”
By using ADVA and Edgecore’s technology in a complete and fully tested DCSG offering, the trial gives Vodafone Romania insight into new mobile transport opportunities. Developed within the Telecom Infra Project’s Open Optical & Packet Transport group, the solution provides an open, agile and scalable solution able to meet today’s protocol requirements and is adaptable with future needs. Its hardware-supported SyncE and IEEE 1588 timing, with optional SFP-based GNSS backup, fulfills the most stringent synchronization accuracy requirements.
“This latest trial highlights how major mobile network operators have an alternative simple and cost-effective route to the deployment for 5G services. Our open and feature-rich Ensemble Activator NOS and Edgecore’s high-performance white boxes free network operators from closed proprietary systems. They enable them to deploy vendor-neutral disaggregated architectures using best-in-class components,” commented Eli Angel, VP, product line management, ADVA. “Today’s customers expect vendors to work side by side and build open solutions that can easily fit into complex heterogeneous environments. But while some in the industry do little more than talk about their commitment to collaboration and openness, we’re continually proving it. Now, trials like this are making the value of our approach abundantly clear.”
“As the leading provider of open network solutions to Tier 1 operators worldwide, and the leading contributor to the OCP, ONF, and TIP open communities, Edgecore understands the requirement to accelerate the innovation of disaggregated open network deployments while moving toward a more consistent and open infrastructure across mobile broadband and transport networks,” noted George Tchaparian, CEO and president, Edgecore Networks. “This successful live trial in Romania is yet another proof point that open networking is robust and deployable in the most demanding network environments.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005010/en/
Social Media:
https://www.facebook.com/pages/ADVA-Optical-Networking/37630238931
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Together AI and HUMAIN Form Strategic Partnership to Accelerate AI Infrastructure and Cloud Services in Saudi Arabia31.8.2026 14:00:00 CEST | Press release
The partnership, which was announced on stage at LEAP, Combines HUMAIN’s AI Infrastructure Foundation with Together’s AI Native Cloud Platform and Global Reach Together AI, a leading San Francisco-based AI Native Cloud platform, and HUMAIN, a PIF company delivering full-stack artificial intelligence capabilities globally, today at LEAP announced a strategic partnership to connect HUMAIN’s rapidly expanding AI compute capacity in Saudi Arabia with global AI-native and enterprise demand. The partnership will include the construction of a new 250 megawatt data center, located in Saudi Arabia. The partnership brings together HUMAIN’s large-scale, multi-chip AI infrastructure footprint, expanding cloud and inference capabilities with Together AI’s global customer ecosystem and AI-native inference platform. Together, the companies will offer an additional option for developers, enterprises, and AI-native organizations worldwide to access high-performance AI infrastructure for inference and t
SLB to Acquire Kelvion, Expanding its Role Across Data Center Infrastructure31.8.2026 12:50:00 CEST | Press release
Scalable, energy-efficient and reliable thermal management technologies will optimize operating performance in increasingly complex data centers and industrial systems SLB (NYSE: SLB) today announced it has signed an agreement to acquire Kelvion, a global provider of thermal management and heat exchange technologies. The acquisition strengthens SLB's Data Center Solutions business with critical thermal management technologies and expands the company's role in data center infrastructure, which is one of the world’s fastest-growing industrial and technology markets. “AI is driving the most significant infrastructure investment cycle in our lifetime,” said Olivier Le Peuch, chief executive officer of SLB. “This transaction accelerates our ambition to become an industrial technology partner to the data center industry and help customers address the growing infrastructure complexity required to scale AI. Kelvion advances our path toward more integrated data center infrastructure solutions,
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release
Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA
GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
